Portal de Periódicos da CAPES

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis

2014; SAGE Publishing; Volume: 21; Issue: 9 Linguagem: Inglês

10.1177/1352458514559865

1477-0970

Tomáš Kalinčík, Vilija Jokubaitis, Guillermo Izquierdo, Pierre Duquette, Marc Girard, Pierre Grammond, Alessandra Lugaresi, Celia Oreja‐Guevara, Roberto Bergamaschi, Raymond Hupperts, François Grand’Maison, Eugenio Pucci, Vincent Van Pesch, Cavit Boz, Gerardo Iuliano, Ricardo Fernández‐Bolaños, Shlomo Flechter, Daniele Spitaleri, Edgardo Cristiano, Freek Verheul, Jeannette Lechner‐Scott, Maria Pia Amato, José Antonio Cabrera-Gómez, María Laura Saladino, Mark Slee, Fraser Moore, Orla Gray, Mark Paine, Michael Barnett, Eva Havrdová, Dana Horáková, Timothy Spelman, Maria Trojano, Helmut Butzkueven, E Roullet, Csilla Rózsa, Krisztián Kása, Carmen Adella Sîrbu, Cameron Shaw, Steve Vucic, Tatjana Petkovska‐Boskova, Joseph Herbert, Ilya Kister, Bhim Singhal, Raed Alroughani, Elizabeth Alejandra Bacile Bacile, Walter Oleschko Arruda, Élaine Roger, Pierre Despault, Mark Marriott, Anneke van der Walt, John King, Jill Byron, Lisa Morgan, E. Glenn Hinson, Jodi Haartsen, Samir Mechati, Erich Bianchi, A. Bulla, Matthieu Corageoud, Giovanna De Luca, V. Di Tommaso, D. Travaglini, Erika Pietrolongo, Maria di Ioia, D. Farina, Luca Mancinelli, Juan Ignacio Rojas, Liliana Patrucco, Elisabetta,

Rheumatoid Arthritis Research and Therapies

Background: The results of head-to-head comparisons of injectable immunomodulators (interferon β, glatiramer acetate) have been inconclusive and a comprehensive analysis of their effectiveness is needed. Objective: We aimed to compare, in a real-world setting, relapse and disability outcomes among patients with multiple sclerosis (MS) treated with injectable immunomodulators. Methods: Pairwise analysis of the international MSBase registry data was conducted using propensity-score matching. The four injectable immunomodulators were compared in six head-to-head analyses of relapse and disability outcomes using paired mixed models or frailty proportional hazards models adjusted for magnetic resonance imaging variables. Sensitivity and power analyses were conducted. Results: Of the 3326 included patients, 345–1199 patients per therapy were matched (median pairwise-censored follow-up was 3.7 years). Propensity matching eliminated >95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b ( p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.